Skip to main content Accessibility help

Obsessive-Compulsive Disorder: An Open-Label Pilot Trial of Escitalopram


Introduction: Selective serotonin reuptake inhibitors are considered the most effective and well-established pharmacotherapy for the treatment of obsessive-compulsive disorder (OCD), a chronic and disabling condition. However, ~40% of patients do not have a significant improvement, suggesting that new medications are needed. This study was designed to investigate the treatment response to escitalopram in OCD patients.

Methods: This open-label study involved 11 adult OCD outpatients diagnosed with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Axis I Disorders. Data were collected and the treatment response was assessed by an experienced psychiatrist by using the Yale-Brown Obsessive-Compulsive Scale. Subjects received escitalopram 30 mg/day for 12 weeks starting at 10 mg/day. Dosage adjustments were made within 2 weeks, depending on the tolerability of the patient.

Results: Six of the 11 patients (54.5%) presented a reduction of at least 40% in the baseline total Yale-Brown Obsessive-Compulsive Scale scores.

Conclusion: Despite the small sample size and the open-label nature of this trial, these data suggest that escitalopram may be a useful option for patients with OCD.


Corresponding author

Please direct all correspondence to: Maria C. Rosário, MD, PhD; E-mail:


Hide All
1.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
2.Karno, M, Golding, JM, Sorenson, SB, Burnam, MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45:10941099.
3.Rasmussen, SA, Eisen, JL. Epidemiology of obsessive compulsive disorder. J Clin Psychiatry. 1990;51(suppl):1013.
4.Kessler, RC, Chiu, WT, Demler, O, Merikangas, KR, Walters, EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617627.
5.Leon, AC, Portera, L, Weissman, MM. The social costs of anxiety disorders. Br J Psychiatry. 1995;27(suppl):1922.
6.Hollander, E, Stein, DJ, Kwon, JH, et al.Psychosocial function and economic costs of obsessive-compulsive disorder. CNS Spectr. 1997;2:1625.
7.Murray, CJ, Lopez, AD. Evidence-based health policy—lessons from the Global Burden of Disease Study. Science. 1996;274:740743.
8.Pallanti, S, Hollander, E, Bienstock, C, et al.Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002;5:181191.
9.Fineberg, NA, Gale, TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2005;8:107129.
10.Pallanti, S, Quercioli, L, Koran, L. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry. 2002;63:796801.
11.Ellingrod, VL. Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature. Pharmacotherapy. 1998;18:936960.
12.Benazon, NR, Ager, J, Rosenberg, DR. Cognitive behavior therapy in treatment-naive children and adolescents with obsessive-compulsive disorder: an open trial. Behav Res Ther. 2002;40:529539.
13.Pediatric OCD Treatment Study Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004;292:19691976.
14.Bloch, MH, Landeros-Weisenberger, A, Kelmendi, B, Coric, V, Bracken, MB, Leckman, JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11:622632.
15.Owens, MJ, Knight, DL, Nemeroff, CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50:345350.
16.Burke, WJ. Escitalopram. Expert Opin Investig Drugs. 2002;11:14771486.
17.Davidson, JR, Bose, A, Wang, Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2005;66:14411446.
18.Stahl, SM, Gergel, I, Li, D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003;64:13221327.
19.Davidson, JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006;67(suppl 12):2026.
20.Robert, S, Hamner, MB, Ulmer, HG, Lorberbaum, JP, Durkalski, VL. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry. 2006;67:15221526.
21.Freeman, EW, Sondheimer, SJ, Sammel, MD, Ferdousi, T, Lin, H. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry. 2005;66:769773.
22.Kennedy, SH, Andersen, HF, Lam, RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci. 2006;31:122131.
23.First, MB, Spitzer, RL, Gibbon, M, et al.Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P). version 2. New York, NY: New York State Psychiatric Institute, Biometrics Research; 1995.
24.Goodman, WK, Price, LH, Rasmussen, SA, et al.The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46:10061011.
25.Goodman, WK, Price, LH, Rasmussen, SA, et al.The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989;46:10121016.
26.Leckman, JF, Riddle, MA, Hardin, MT, et al.The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989;28:566573.
27. Statistical Package for Social Sciences–SPSS for Windows. version 12.0. Chicago, III: SPSS Inc.
28.Schruers, K, Koning, K, Luermans, J, Haack, MJ, Griez, E. Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand. 2005;111:261271.
29.Bareggi, SR, Bianchi, L, Cavallaro, R, Gervasoni, M, Siliprandi, F, Bellodi, L. Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs. 2004;18:329335.
30.Montgomery, SA, Kasper, S, Stein, DJ, Bang Hedegaard, K, Lemming, OM. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001;16:7586.
31.Mundo, E, Bianchi, L, Bellodi, L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol. 1997;17:267271.
32.Stein, DJ, Montgomery, SA, Kasper, S, Tanghoj, P. Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001;16:357361.
33.Fineberg, NA, Tonnoir, B, Lemming, O, Stein, DJ. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2007;17:430439.
34.Stein, DJ, Andersen, EW, Tonnoir, B, Fineberg, N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-weekstudy. Curr Med Res Opin. 2007;23:701711.
35.Shavitt, RG, Belotto, C, Curi, M, et al.Clinical features associated with treatment response in obsessive-compulsive disorder. Compr Psychiatry. 2006;47:276281.
36.Rosario-Campos, MC, Leckman, JF, Mercadante, MT, et al.Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry. 2001;158:18991903.

Obsessive-Compulsive Disorder: An Open-Label Pilot Trial of Escitalopram


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed